2019 HESTIA 3 – A Randomised, Double-Blind, Parallel-Group, Multi-centre, Phase 3 Study to Evaluate the Effect of Ticagrelor vs Placebo in Reducing the Rate of Vaso-Occlusive Crises in Pediatric Patients with Sickle Cell Disease
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros.
Previous Post2018 HESTIA 4 – A Multi-centre, Phase 1, Open-label, Single-Dose Study to Investigate Pharmacokinetics (PK) of Ticagrelor in Infants and Toddlers, Aged 0 to less than 24 months, with Sickle Cell Disease
Next Post2017 GBT 031 – A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multi-Centre Study of GBT 440 Administered Orally to Patients with Sickle Cell Disease
